cooperates with oncogenic Ras to induce cellular transformation, which requires cell cycle-dependent phosphorylation of C/EBPb on Ser 64 and Thr 189 . 3, 9 C/EBPb is required for Rasinduced skin tumorigenesis as C/EBPb À/À mice are completely resistant to mouse skin tumorigenesis initiated by topically applied carcinogens such as 7,12-dimethylbenz[a]anthracene (DMBA), 3 which functions through its ability to produce oncogenic Ras mutations. 10 DMBA treatment of mouse skin produces benign papillomas of which greater than 95% contain an activating A-T mutation in codon 61 of Ras. 10 Carcinogen-induced oncogenic mutation of codon 61 can occur in 0.1-5% of Ras genes by error-prone repair within 1-3 days after treatment. 11 Treatment of C/EBPb À/À mouse skin with DMBA results in aberrant increases in p53 levels and function, which is responsible for the vast anomalous induction of apoptosis in 1-2% of C/EBPb À/À keratinocytes within 1 day of treatment. 4 Collectively, these studies suggest that C/EBPb may be required for the survival of DMBAinitiated oncogenic Ras-containing tumor precursor cells in mouse skin through the regulation of p53 levels and function.
Although it is known that the aberrant increase in p53 is responsible for the proapoptotic phenotype in DMBA-treated C/EBPb À/À mice, it is not known whether this increase is due to oncogenic Ras. p53 is stabilized and activated in response to different types of stress including oncogenic stress, DNA damage, hypoxia, and nutrient deprivation. 12 Oncogenic Ras regulates p53 levels and activity through multiple mechanisms. 13 An important, well-established mechanism involves the induction of p19
Arf . 12 Oncogenic Ras induces p19 Arf gene expression through regulation of transcription factors such as Dmp1, AP-1 (JunD, c-Jun, FRA1), and E2F1. [14] [15] [16] Induced p19
Arf functions by inhibiting the negative feedback loop between p53 and Mdm2, resulting in p53 stabilization and eventually growth arrest or apoptosis. 17 Oncogenic Ras can also induce p53-dependent senescence both in culture and in vivo, in part, through activation of DNA-damage response pathways. [18] [19] [20] The mechanism through which oncogenic Ras activates DNA-damage response pathways is not clear, but may be due to aberrant DNA replication, resulting in the generation of DNA strand breaks followed by activation of DNA-damage response kinases, ATM/ATR. 20 ATM/ATR are the central components of the DNA-damage response induced by both replication stress and DNA-damaging agents that directly alter DNA structure. 21 ATM/ATR activation results in phosphorylation of p53, through direct and indirect mechanisms. 21 ATM and ATR also contribute to p53 activation by phosphorylating Mdm2, MdmX, and/or E2F1, modulating their ability to regulate p53. 21 These post-translational modifications result in increased p53 stability and activity. 21 The fact that C/EBPb is a downstream effector of oncogenic Ras coupled with ample evidence linking oncogenic Ras to p53 prompted us to investigate whether carcinogen-induced aberrant increases in p53 and apoptosis in C/EBPb À/À mice are a result of oncogenic Ras-induced signaling. We demonstrate that p19
Arf is upregulated in C/EBPb À/À mouse epidermis. However, oncogenic Ras activation and upregulated p19
Arf expression are not required for the atypical induction of p53 and apoptosis in C/EBPb À/À mice. Instead, we found that DNA damage results in anomalous increases in p53 and apoptosis, indicating that C/EBPb functions downstream of DNA damage to repress p53 and apoptosis.
Results

p19
Arf is specifically deregulated in C/EBPb À/À mouse epidermis and primary epidermal keratinocytes. To begin to determine whether C/EBPb regulates p53 through a mechanism involving p19
Arf , we first examined p19
Arf expression in untreated C/EBPb À/À and wild-type mouse epidermis. Surprisingly, we observed a dramatic 35-fold increase in p19
Arf mRNA levels in the epidermis of C/EBPb À/À mice compared to wild type ( Figure 1a ). p19 Arf protein levels were also significantly increased in epidermal lysates from C/EBPb À/À mice ( Figure 1b ). This increase in p19 Arf was Arf promoter reporter construct and either empty vector or a C/EBPb expression vector. Data represent mean ± S.E. *Significantly different from basal activity of the p19
Arf promoter reporter, as determined by two-factor ANOVA (N ¼ 3 independent experiments, Po0.05) independent of increased Ras levels and was associated with a modest increase in p53 protein levels ( Figure 1b ). Our observation that p19 Arf is highly expressed in C/EBPb À/À mouse epidermis was unexpected as p19 Arf is not detectable in most normal adult tissues. 22, 23 The INK4a-Arf locus encodes both p19
Arf and p16 INK4a . 24 Although they have unique promoters, p19
Arf and p16 INK4a tumor suppressor genes are often coordinately regulated. 25 To determine whether p19
Arf expression is specifically upregulated in C/EBPb À/À mice, or whether p16 INK4a expression is similarly altered, we examined p16
INK4a mRNA levels from untreated C/EBPb À/À and wild-type mouse epidermis (Figure 1c ). p16
INK4a expression was not significantly altered, indicating that p19
Arf is specifically deregulated in C/EBPb À/À mice. Analysis of the proximal 2.6 kb of the p19
Arf promoter revealed the identification of several putative C/EBP-binding sites. Cotransfection of C/EBPb and a 2.6-kb p19 Arf promoter reporter demonstrated that C/EBPb significantly repressed the activity of the p19
Arf promoter reporter by 40% (Figure 1d ), suggesting that C/EBPb may directly repress p19
Arf expression. Although not expressed at detectable levels in most normal adult tissues, p19
Arf expression is readily induced by 'culture shock' when primary cells are placed in culture. 26 To investigate whether p19
Arf expression is also deregulated in C/EBPb À/À keratinocytes in response to 'culture shock', we examined p19
Arf mRNA and protein levels in wild-type and C/EBPb À/À primary epidermal keratinocytes. C/EBPb À/À primary keratinocytes displayed a consistent, significant increase in both p19 Arf mRNA and protein levels over that observed in wild-type keratinocytes (Figure 2a and b) . These results indicate the deregulation of p19
Arf is due to a keratinocyte-intrinsic defect.
We performed p19 Arf immunohistochemistry to localize the expression of p19
Arf in skin. p19 Arf was detected in C/EBPb À/À mouse skin, but not in wild-type or in the negative control p19 ArfÀ/À mouse skin (Figure 2c ). p19 Arf was expressed in a sub-population of C/EBPb À/À suprabasal keratinocytes located within the upper infundibulum area of the hair follicle. p19
Arf localized to nuclei and displayed distinct nucleolar staining. These results demonstrate that p19
Arf is greatly increased in C/EBPb À/À mouse epidermis and primary keratinocytes and is most highly expressed in keratinocytes within the infundibulum of the hair follicle.
Arf is not required for carcinogen-induced anomalous increases in p53 and apoptosis in C/EBPb À/À mice. As p19
Arf levels are dramatically increased in C/EBPb À/À mouse epidermis, we hypothesized that C/EBPb À/À epidermal keratinocytes may be 'primed' to rapidly stabilize and activate p53 following DMBA-induced oncogenic Ras activation, resulting in increased cell death compared to wild-type epidermis. To determine whether elevated p19
Arf in Figure 2 p19 Arf is deregulated in C/EBPb À/À primary epidermal keratinocytes and is most highly expressed in a sub-population of keratinocytes within C/EBPb , and C/EBPb À/À ;p19 ArfÀ/À compound mouse epidermis ( Figure  3a and b) . C/EBPb À/À mice displayed a significant increase in p53 and apoptosis compared with wild type following carcinogen treatment. 4 C/EBPb À/À ;p19 ArfÀ/À compound mice displayed similar anomalous increases in p53 and apoptosis levels compared with C/EBPb À/À mice, indicating that upregulation of p19
Arf in C/EBPb À/À mouse epidermis is not responsible for the abnormal induction of p53 or apoptosis following DMBA treatment. Representative photomicrographs of p53-immunostained and H and E-stained skin sections showing apoptotic keratinocytes of each of the four DMBA-treated genotypes are shown in Figure 3c .
Oncogenic Ras activation is not sufficient to trigger atypical increases in p53 and apoptosis in C/EBPb À/À mice. Previous studies from our laboratory demonstrated that forced expression of oncogenic Ras in C/EBPb À/À primary keratinocytes in culture does not elicit increased apoptosis (data not shown). One possible explanation for this result is that an in vivo epidermal/dermal microenvironment is required for oncogenic Ras to induce aberrant apoptosis in C/EBPb À/À epidermal keratinocytes. To elucidate whether activation of oncogenic Ras signaling, itself, can elicit aberrant increases in p53 and apoptosis in C/EBPb À/À mice, we generated K14-ER:Ras;C/EBPb À/À compound mice. K14-ER:Ras mice are genetically engineered mice that utilize the keratin 14 (K14) promoter to target the expression of the ER:oncogenic RasV12 fusion protein to basal keratinocytes of mouse epidermis. The activity of ERRas is regulated through topical treatment with the synthetic ER antagonist, 4-hydroxytamoxifen (4-OHT). 27 As shown in Figure 3 p19 Arf is not required for carcinogen-induced anomalous increases in p53 and apoptosis in C/EBPb
, and C/EBPb
ArfÀ/À mice were treated topically with 400 nmol DMBA and 20 h later, skin sections were prepared. Skin sections were used to quantify (a) p53-positive basal keratinocytes and (b) apoptotic basal keratinocytes in mouse skin. Data represent mean ± S.E. Four skin sections from each of at least three independent mice for each genotype were examined for p53-positive staining or apoptosis. There were no significant difference observed in p53-positive keratinocytes per cm (P ¼ 0.769) or apoptotic keratinocytes per cm (P ¼ 0.505) between C/EBPb À/À and C/EBPb To determine whether activation of oncogenic Ras elicits altered regulation of p53 and apoptosis in C/EBPb À/À mice, we examined p53 and apoptosis levels in skin sections from DNA-damaging agents induce aberrant increases in p53 and apoptosis in C/EBPb À/À mouse epidermis. To determine whether direct carcinogen-induced DNA damage elicits altered regulation of p53 and apoptosis in C/EBPb À/À mice, we examined the effects of various types of DNAdamaging agents in C/EBPb À/À mice compared with C/EBPb þ / þ . As shown in Figure 5a , topical treatment with N-methyl-N 0 -nitro-N-nitrosoguanidine (MNNG) produced a significant increase in the number of p53-positive keratinocytes in C/EBPb À/À mouse epidermis compared with C/EBPb þ / þ mice. C/EBPb À/À mice also displayed an anomalous increase in apoptosis when compared to wild type ( Figure 5b ). In general, these increases were observed across the entire 16-h time course. As MNNG is known to produce oncogenic Ras mutations in mouse skin, 28 we examined the effects of ultraviolet B (UVB) radiation in C/EBPb À/À mice. UVB produces DNA damage mostly in the form of cyclobutane pyrimidine dimers and 6, 4 photoproducts that do not involve mutation of Ras. As shown in Figure 5c , p53 was rapidly and significantly increased in C/EBPb À/À mice compared with C/EBPb mice as early as 3 h after UVB treatment. Similarly, UVB exposure induced a significant increase in apoptosis in C/EBPb À/À mice compared with wild type (Figure 5d ). Similar results were obtained using terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) staining (data not shown). These results demonstrate that different types of DNA damage induce anomalous increases in p53 and apoptosis in C/EBPb À/À mice. Previous studies demonstrated that the DMBA-induced proapoptotic phenotype in C/EBPb À/À mice was dependent on p53 levels and function. 4 DMBA functions as a carcinogen by inducing activating oncogenic Ras mutations. 10 Our results 
À/À mice were treated topically with 100 mJ/cm 2 of UVB, and the treated dorsal skin was collected 15 h following treatment. Skin sections were used to quantify apoptotic interfollicular basal keratinocytes. Data represent mean ± S.E. One-way ANOVA demonstrated significance for increased apoptosis for genotype following UVB treatment. *Significantly different from each genotype (NX3 for all time points, Po0.05). (f) Representative p53 immunohistochemical staining or H and E staining (apoptosis) of C/EBPb þ / þ and C/EBPb À/À mouse epidermis collected either before (0 h) or after treatment with UVB (6 h). Arrows indicate p53-positive or apoptotic basal epidermal keratinocytes, respectively suggest that increased apoptosis in C/EBPb À/À mice is a result of DNA damage independent of oncogenic Ras. Thus, we wanted to determine whether p53 is required for increased apoptosis in C/EBPb À/À mice following treatment with a DNAdamaging agent that functions independently of oncogenic Ras. To investigate this, we treated C/EBPb þ / þ , p53 À/À , C/EBPb À/À , and C/EBPb À/À ;p53 À/À mice with UVB and determined the number of apoptotic keratinocytes 15 h after treatment (Figure 5e ). C/EBPb À/À ;p53 À/À mice responded with low levels of apoptosis, similar to that observed for C/EBPb þ / þ and p53 À/À control mice. In contrast, C/EBPb
mice displayed a significant increase in apoptosis in response to UVB, similar to results shown in Figure 5d . Representative images of p53 immunohistochemical staining and apoptosis (H and E staining) of C/EBPb þ / þ and C/EBPb À/À mice before or after UVB exposure are shown (Figure 5f ). These results demonstrate that aberrant apoptosis in C/EBPb À/À mice following UVB-induced DNA damage is p53-dependent.
Intraperitoneal injection of cyclophosphamide in C/EBPb
À/À mice induces aberrant increases in p53 and apoptosis in skin keratinocytes. Our results indicate the loss of C/EBPb functions to increase the sensitivity of cells to apoptosis induced by DNA-damaging agents. On the basis of these results, we hypothesized that the loss of C/EBPb would enhance the effectiveness of alkylating chemotherapeutic agents. To examine this, we injected cyclophosphamide intraperitoneally into C/EBPb þ / þ and C/EBPb À/À mice and examined p53 levels and apoptosis at the remote skin location. Cyclophosphamide is a chemotherapeutic drug given as treatment for various types of cancer including leukemia, lymphoma, breast, ovarian, and bladder. Intraperitoneal injection of cyclophosphamide in C/EBPb À/À mice resulted in a significant induction of p53 and apoptosis in the skin interfollicular basal keratinocytes over that observed in similarly treated C/EBPb þ / þ mice (Figure 6a  and b) . These results indicate that the loss of C/EBPb cooperates with the alkylating chemotherapeutic agent, cyclophosphamide, to enhance cell death.
C/EBPb ablation is associated with increased post-translational modification of p53, and p53 transactivation activity is inhibited by C/EBPb. DMBA treatment of C/EBPb À/À mice results in increased p53 protein levels without any increase in p53 mRNA levels, 4 suggesting that the aberrant increase in p53 protein in the epidermis of DMBA-treated C/EBPb À/À mice is not due to increased transcription of p53. To further address the role of C/EBPb in p53 regulation, we conducted ChIP experiments on C/EBPb þ / þ primary keratinocytes to determine whether C/EBPb was bound to the p53 promoter at a site reported to be a bona fide C/EBP binding site. 29 We were unable to demonstrate any binding of C/EBPb to this area of the p53 promoter. In addition, we did not observe any differential regulation by C/EBPb of a mouse p53 promoter reporter, which contained the 1.2 kb proximal region of the p53 promoter with or without the above-mentioned C/EBP site (data not shown). 29 We conclude that it is unlikely that C/EBPb directly regulates transcription of p53 in keratinocytes. We next examined whether post-translational modifications associated with enhanced p53 stabilization (mouse S23 ¼ human S20) and transactivation (mouse S389 ¼ human S392) were differentially present in DMBAtreated C/EBPb
mice. Using phospho-specific p53 antibodies, we observed that the phosphorylation of both S23 and S389 were significantly increased in DMBA-treated C/EBPb À/À mice (Figure 7a ). These results suggest that the aberrant increases in p53 protein and function in DMBA-treated C/EBPb À/À mice involve alterations in post-translational modifications of p53. Finally, using a p53-responsive promoter reporter, we observed that C/EBPb could repress p53 transcriptional activity in keratinocytes (Figure 7b ). These data are consistent with previous findings in human endometrial stromal cells. 30 Our results indicate that the ablation of C/EBPb is associated with post-translational modifications of p53, and C/EBPb can inhibit the transcriptional activity of p53 in keratinocytes. 
and C/EBPb
À/À mice were treated (i.p.) with 250 mg per kg body weight of cyclophosphamide, and the dorsal skin was collected at the indicated times following treatment. Skin sections were used to quantify (a) p53-positive or (b) apoptotic interfollicular basal keratinocytes. Data represent mean ± S.E. Two-way ANOVA demonstrated significance for the increase in p53-positive keratinocytes and increase in apoptosis for genotype, time, and the interaction between genotype and time following cyclophosphamide treatment. *Significantly different from C/EBPb þ / þ at the same time point (NX3 for all time points, Po0.05)
Discussion
As described in the introduction, there is a substantial body of evidence that suggested the enhanced proapoptotic response in C/EBPb À/À epidermal keratinocytes is likely a result of carcinogen-induced oncogenic Ras activation. Using K14-ER:Ras;C/EBPb À/À mice, we observed that conditional activation of oncogenic Ras12V in epidermal basal keratinocytes of C/EBPb À/À mouse epidermis was insufficient to induce anomalous increases in p53 and apoptosis. Our results indicate that the proapoptotic phenotype in carcinogen-treated C/EBPb À/À mice is not due to oncogenic Ras. Instead, we observed that treatment with a diverse group of DNA-damaging agents, including UVB radiation, MNNG, DMBA, and cyclophosphamide all resulted in abnormal increases in p53 and apoptosis. These findings indicate that C/EBPb participates in the DNA-damage response network and functions to promote cell survival by repressing p53 levels and function in response to DNA damage. Although a parallel increase in p53 and apoptosis in C/EBPb À/À mouse epidermis was observed following exposure to DNA-damaging agents, apoptosis was found to persist after p53 levels returned to control levels. As induction of p53 is an early event in apoptosis and apoptosis requires approximately 4 h from commitment to termination, 31 this could contribute to the sustained apoptosis that is observed in C/EBPb À/À mice.
Regulation of p53 is complex, involving at least 10 positive and negative feedback loops that modulate p53 expression, stability, and activity. 32 It is not yet known how C/EBPb participates within the DNA-damage signaling cascade to repress p53 levels and function. C/EBPb can function as a transcriptional repressor. [33] [34] [35] [36] Basal p53 mRNA levels were increased 2.5-fold in C/EBPb À/À mouse epidermis compared with wild-type mice, suggesting a repressor function for C/EBPb in the regulation of basal p53 mRNA levels. 4 However, DMBA treatment did not further increase p53 mRNA levels, indicating that the increased p53 protein levels in DMBA-treated C/EBPb À/À mouse epidermis are not due to upregulation of p53 mRNA. 4 On the basis of these results and results presented in the current study, it is unlikely that C/EBPb regulates the transcription of p53 in epidermal keratinocytes in response to DNA damage. DNA-damage response pathways may modulate C/EBPb levels or activity, thereby altering the ability of C/EBPb to regulate the expression of genes or activity of proteins involved in posttranslational modification of p53. Accordingly, C/EBPb protein levels are induced in keratinocytes following exposure to UVB. 37 Elevated levels of C/EBPb may repress p53 by regulating the expression of genes that contribute to phosphorylation, acetylation, or sumoylation of p53 following DNA damage. Our results indicate ablation of C/EBPb is associated with increased post-translational modifications of p53, which are known to enhance p53 stability and activity. Additional studies are required to determine whether these changes are a cause or consequence of elevated p53. C/EBPb has been shown to interact with p53, disrupting p53 DNA binding and transcriptional activity, 30 and we provide evidence that this mechanism of inhibition of p53 transcriptional activity by C/EBPb also occurs in keratinocytes. This mechanism could contribute to the negative regulation of p53 by C/EBPb and loss of C/EBPb could result in abnormally elevated p53-mediated apoptosis observed in C/EBPb À/À mice treated with DNA-damaging agents.
Although we demonstrate that direct DNA damage is an important signal in eliciting C/EBPb-mediated repression of p53 to promote keratinocyte cell survival, additional mechanisms in other cell types contribute to C/EBPb-mediated cell survival. 5, 6 For example, CCl 4 treatment, which induces DNA damage through the generation of free radicals, results in phosphorylation of C/EBPb by ribosomal protein 6-kinase, producing a functional XEXD caspase substrate/inhibitor box that is critical for survival of hepatic stellate cells. 5 In addition, C/EBPb is required for growth factor-dependent survival of Myc/Raf-transformed macrophages through an autoregulatory pathway involving IGF-1.
6 Activation of several oncogenes including Myc, Ras, Raf, cyclin E, Cdc25A, and E2F1 can engage DNA-damage response pathways, resulting in activation of p53 and the induction of apoptosis or senescence. 18, 20, 38 The important decision of cell survival or cell death in response to different stimuli is likely controlled by more than one signal. Thus, it is possible that there is overlap of these pathways in their ability to contribute to C/EBPbmediated cell survival depending on the cellular and genetic context.
Our results reveal that p19 Arf is upregulated in untreated C/EBPb À/À mouse epidermis and primary keratinocytes. The 
magnitude of p19
Arf expression in C/EBPb À/À mouse epidermis was unexpected because p19
Arf is not detectably expressed during embryonic development and is found at very low levels and only in a small subset of normal adult tissues, such as the testes. 22, 23 Localization of p19 Arf in C/EBPb À/À mouse skin demonstrated that p19 Arf was detectable in the nucleoli of keratinocytes in the infundibulum of the hair follicle. We observed that p19
Arf is not upregulated in the epidermis of mice in which C/EBPa has been ablated (unpublished results), demonstrating that the regulation of p19
Arf is C/EBP isoform specific to C/EBPb. The biological significance of deregulated p19
Arf in C/EBPb À/À mouse skin and exactly how C/EBPb regulates p19
Arf expression remains to be determined. p19 Arf is known for its role as a tumor suppressor gene, through its ability to inhibit Mdm2 and thereby derepress p53. 17 However, p19
Arf functions through p53-independent mechanisms, including the direct repression of E2F1 or c-Myc transcriptional activity. 17 Although our results indicate that p19 Arf is not involved in the p53-dependent proapoptotic phenotype in DMBA-treated C/EBPb À/À mice, it is unclear whether or not p19
Arf functions to influence C/EBPb À/À mouse skin homeostasis or tumorigenesis. p19
Arf expression is under strict regulation, as revealed by the increasing number of transcription factors such as Pokemon, E2F3b, p53, Twist, Bmi1, Tbx2/3, and JunD, which repress p19
Arf . 25 Our results suggest that C/EBPb may also contribute to the negative regulation of p19
Arf through a mechanism involving repression of the p19
Arf proximal promoter. In summary, our results indicate that C/EBPb represses p53 to promote cell survival downstream of DNA damage. These findings uncover a novel link between the DNAdamage response pathway, C/EBPb, and the repression of p53 to promote cell survival. The fact that the loss of C/EBPb significantly enhances the proapoptotic effect of systemically administered cyclophosphamide, an alkylating chemotherapeutic, suggests that C/EBPb may be a molecular target for cotherapy. The inhibition of C/EBPb in p53-proficient tumor cells could cooperate with alkylating chemotherapeutic agents to enhance apoptosis and tumor regression. . 39 Mice were genotyped as described by the MMHCC PCR protocol for strain no. 01XG7. p19
ArfÀ/À female mice were crossed with C/EBPb À/À male mice.
Arf þ /À ) were crossed to generate all genotypes utilized in these studies. K14-ER:Ras mice were a kind gift from Dr. Paul Khavari (Stanford University, CA, USA).
27 K14-ER:Ras female mice were crossed with C/EBPb À/À male mice to generate K14-ER:Ras;C/EBPb þ /À mice. K14-ER:Ras;C/EBPb þ /À mice were crossed with B6.129-C/EBPb þ /À mice to generate all genotypes used in these studies. Mice were genotyped for ER:Ras by PCR using the following primers: forward, CACCACCAGCTCCACTTCAGCACATT; reverse, CGCACCAACGTGTA GAAGGCATCCTC. The dorsal hair of mice (7-11 weeks old) was clipped with electric clippers at least 2 days before use. Mice were treated as described in the text. DMBA (catalog no. 40818, Fisher Scientific USA -Acros Organics, Pittsburgh, PA, USA) was dissolved in acetone (400 nmol/200 ml). 4-OHT (catalog no. H7904) and MNNG (catalog no. 12994-1) were purchased from Sigma (St. Louis, MO, USA). 4-OHT was dissolved in 95% ethanol (1 mg/100 ml). MNNG was dissolved in acetone (2.5 mmol/200 ml of acetone). Mice were treated with cyclophosphamide monohydrate (Sigma, catalog no. C0768) prepared in phosphate-buffered saline (PBS, 25 mg/ml) by intraperitoneal injection at a final dose of 250 mg per kg body weight. The UV lamp used in this study, purchased from UVP Inc. (catalog no. 34-0039-01; Upland, CA, USA), emits wavelengths between 280 and 350 nm with a spectrum peak at 312 nm. The light intensity of the lamp was measured using the IL-1400A radiometer (International Light, Newburyport, MA, USA) equipped with the SEL240/UVB-1 sensor, which detects wavelengths between 265 and 332 nm. Mice were treated with 100 mJ/cm 2 of UVB radiation.
Cell lines and cell culture. Balb/MK2 mouse keratinocytes (Bernard Weissman, University of North Carolina, NC, USA) were cultured as described previously. 37 Mouse primary epidermal keratinocytes were isolated from newborn C/EBPb þ / þ or C/EBPb À/À littermates as described previously. 37 Isolated keratinocytes were plated at 3 Â 10 6 cells per well in six-well culture dishes in complete media (Ca 2 þ -free EMEM supplemented with 10% non-Chelex-treated FBS, 10 ng of hEGF per ml, 100 U of penicillin per ml, 100 mg of streptomycin per ml, and 250 ng of amphotericin B per ml) for 4 h. Cultures were gently washed with Mg 2 þ -and Ca 2 þ -free PBS and re-fed with keratinocyte serum-free medium (Ca 2 þ -free K-SFM supplemented with 2.5 mg of hEGF, 25 mg bovine pituitary extract, 5 mg of gentimycin per ml, and calcium chloride to a final concentration of 0.05 mM). Three independent pools of isolated primary keratinocytes were examined for p19
Arf mRNA and protein expression at each time point. Primary keratinocytes collected at time 0 were isolated as above; 1 Â 10 6 cells were pelleted by centrifugation and subsequently used to harvest total RNA or protein lysates as described.
Construction of pGL4.10-p19
Arf 2.6 kb promoter reporter and luciferase assay. pGL2-p19 Arf 2.6 kb promoter reporter was kindly provided by Kazushi Inoue (Wake Forest University, NC, USA). The p19 Arf 2.6 kb promoter fragment was cloned into pGL4.10 using KpnI and BglII. Balb/MK2 keratinocytes were cotransfected in 12-well plates with 300 ng per well of pGL4.10-p19 Arf 2.6 kb or pGL4.10 and the indicated amounts of pcDNA3.1(À)-C/EBPb expression plasmids using Lipofectamine (Invitrogen, Carlsbad, CA, USA) in triplicate. Cells were washed with ice-cold PBS, lysed in 1 Â Cell Culture Lysis Buffer (Promega, Madison, WI, USA), harvested by scraping, and cleared by centrifugation before analyzing for luciferase activity. Data were normalized to total protein and activity of the empty reporter construct. The average relative fold change compared to p19 Arf basal promoter activity, arbitrarily set to 1, for three independent experiments are shown ± S.E. A two-factor ANOVA was conducted on the relative fold-change values. To test for repression, a t-test, using the pooled ANOVA error, was carried out for each treatment to test the null hypothesis that mean relative fold change ¼ 1 versus the alternative that mean relative fold change o1.
The p53-responsive promoter reporter constructs (P133/70) and the negative control lacking the p53-responsive promoter (P133/41) have been described previously 40 and were a kind gift from Thomas Eling (National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA). Balb/MK2 keratinocytes were cotransfected in 12-well plates with 400 ng per well of P133/70 or P133/41 and the indicated expression vectors at 200 ng per well (empty vector (pcDNA3.1), C/EBPb, p53, or C/EBPb and p53) using FastTransfect reagent (catalog no. E2431, Promega). Total DNA transfected was maintained at a constant level for all the wells using pcDNA3.1. Cells were lysed 48 h post-transfection and processed as described above. Data are described as the average fluorescence units normalized to total protein±S.E.
Quantitative real-time RT-PCR. Total RNA was collected and prepared for quantitative real-time RT-PCR as previously described. 4 Detection of p19 Arf mRNA levels was conducted using a Cdkn2a (p19 Arf ) TaqMan s Gene Expression Assay (catalog no. Mm01257348_m1; Applied Biosystems, Foster City, CA, USA).
Sequences for p16
INK4a primers and dual-labeled probe were provided by Bryan Betz (National Institute of Environmental Health Sciences), synthesized by Sigma Genosys, and used at a final concentration of 0.5 mM (forward primer: CCCAAC GCCCCGAACT, reverse primer: GTGAACGTTGCCCATCATCA, probe: [FAM]TTT CGGTCGTACCCCGATTCAGGTG [TAM] ). Each independent sample was run in triplicate. Expression levels for in vivo samples were normalized to 18S (Applied Biosystems) and expression levels for primary keratinocyte samples were normalized to GAPDH (Applied Biosystems). Data were analyzed using the comparative C T method and presented relative to the control, C/EBPb þ / þ , or C/EBPb þ / þ at time zero. N ¼ 4-8 mice/genotype for in vivo analysis and N ¼ 3 independent pooled keratinocytes/time for the primary keratinocyte experiment.
Preparation of protein lysates. Isolation of protein lysates from epidermal homogenates was performed as previously described, 4 with the exception that samples were homogenized on ice before sonication. For preparation of protein lysates from cultured primary keratinocytes, cells were washed with cold PBS, harvested by scraping, and collected by centrifugation. Cells were lysed on ice in radioimmunoprecipitation buffer (1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 1 mM phenylmethylsulfonyl fluoride, 1 mM sodium orthovanadate, and 1 Â protease inhibitor cocktail (Roche, Basel, Switzerland) in PBS), sonicated and cleared by centrifugation at 14 000 Â g for 10 min. Supernatants were stored at À80 1C until use. Protein concentration was determined by Bio-Rad Protein Assay reagent (Bio-Rad, Hercules, CA, USA).
Immunoblot analysis. Equal amounts of protein (10-40 mg) were dissolved in SDS sample buffer, boiled, and separated on 12% SDS-polyacrylamide gel electrophoresis. Immunoblot analysis was conducted as described previously. Immunohistochemical staining. Untreated or treated, dorsal skin was excised and fixed for 24 h in 10% neutral-buffered formalin. Four independent areas of skin were collected, embedded in paraffin, and cut into sections (E5 mM). For p53 immunohistochemical staining, sections were deparaffinized, treated with 3% H 2 O 2 , and subjected to antigen retrieval with citrate buffer (pH 6.0) in a 95 1C water bath for 30 min. Sections were blocked with normal goat serum for 30 min at room temperature and then incubated with rabbit polyclonal anti-p53 antibody (catalog no. sc-6243, 1 : 500), purchased from Santa Cruz Biotechnology, at 4 1C for 24 h. For phospho-specific p53 immunohistochemical staining, the following antibodies were purchased from Cell Signaling Technology Inc. (Danvers, MA, USA): rabbit polyclonal anti-phospho-p53-(Ser20) (catalog no. 9287, 1 : 200) and anti-phosphop53-(Ser392) (catalog no. 9281, 1 : 300). Staining for phospho-specific p53 was conducted in the same way as for wild-type p53. Sections were subsequently incubated with biotinylated goat anti-rabbit IgG at room temperature for 30 min. Staining was detected using the rabbit Vectastain Elite ABC kit (catalog no. PK-6101) from Vector Laboratories (Burlingame, CA, USA) and 3,3 0 -diaminobenzidine (DAB) (BioGenex, San Ramon, CA, USA) following the manufacturers' protocols. The sections were counterstained with hematoxylin, dehydrated, and mounted. Data are expressed as the average number of p53-positive staining interfollicular basal keratinocytes per centimeter of mouse skin ± S.E. p19
Arf immunohistochemical staining was modified from a previously described method 23 by Bryan Betz (National Institute of Environmental Health Sciences). Briefly, paraffinembedded sections from mouse skin were deparaffinized and subjected to antigen retrieval in antigen decloaker citrate buffer (pH 6.0) (Biocare, Concord, CA, USA) for 45 min in the decloaking chamber (Biocare). After cooling, slides were treated with 3% H 2 O 2 to quench endogenous peroxide activity. Sections were blocked with normal rabbit serum in 0.1% Triton X-100/PBS for approximately 1 h at room temperature. Rat polyclonal anti-p19
Arf primary antibody (catalog no. 05-929), purchased from Upstate (Chicago, IL, USA), was diluted 1 : 15 in 0.1% Triton X-100/ PBS and added to sections for incubation at 4 1C overnight. Sections were subsequently incubated with biotinylated rabbit anti-rat IgG at room temperature for 30 min. Staining was detected using the rat Vectastain Elite ABC kit (catalog no. PK-6104) and DAB, following the manufacturers' protocols. The sections were counterstained with hematoxylin, dehydrated, and mounted. In vivo BrdU labeling and immunohistochemical staining were conducted by administering 100 mg per kg body weight of BrdU in 200 ml of PBS by i.p. injection 1 h before killing the mice. Skin sections were deparaffinized, incubated in 2 M HCl for 30 min at 37 1C, washed in borate buffer for 3 min at room temperature, followed by digestion in 0.001% trypsin for 3 min at 37 1C. Endogenous peroxidase activity was inhibited by incubation in 3% H 2 O 2 for 10 min. Sections were blocked in horse serum for 20 min and then incubated in anti-BrdU IgG primary antibody (catalog no. 347580; BD Biosciences, San Jose, CA, USA) at a dilution of 1 : 25 for 1 h at room temperature. Slides were further processed using the Vectastain Elite mouse ABC kit (catalog no. PK-6102). Immunohistochemical staining for BrdU was quantified and summarized as the average number of BrdU-positive interfollicular basal keratinocytes per centimeter of mouse skin ± S.E., NX3.
Detection of apoptotic keratinocytes. Mouse skin sections stained with H and E were used to quantify the presence of apoptotic keratinocytes. As previously described, 3, 4 apoptotic keratinocytes in the interfollicular basal epidermis were scored positive if all three of the following criteria were present: dark pyknotic nuclei, cytoplasmic eosinophilia, and absence of cellular contacts. TUNEL staining was conducted as previously described 4 to confirm the apoptosis results obtained using H and E-stained sections. Data are presented as the average number of apoptotic keratinocytes per centimeter of mouse skin±S.E.
Statistical analysis. Statistical analysis was performed as described in the text using SASv9.1.3 Service Pack 4.
